Evercore ISI upgraded Repligen (RGEN) to Outperform from In Line with a price target of $155, up from $130. The firm believes the bioprocessing solutions end market is “relatively insulated” from macro headwinds and is now back now back to a normal high-single-digit growth cadence. Evercore believes Repligen’s new business is delivering while its new modalities overhang “is seemingly removed.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGEN:
- Repligen price target raised to $205 from $204 at RBC Capital
- Repligen Appoints Violetta Hughes as Chief Accounting Officer
- Repligen announces strategic partnership with Novasign
- Repligen’s Strong Market Position and Growth Prospects Justify Buy Rating
- Repligen’s Earnings Call Highlights Robust Growth